Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e-Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

JHOP - February 2020 Vol 10, No 1

Symptom Management Overview

Case Reports

Inadequate Transdermal Patch Absorption in a Patient with Scleroderma Associated with Graft-versus-Host Disease

Robert Mancini, PharmD, BCOP; Mallori Hooker, NP-C, AOCNP, BMTCN; William Kreisle, MD

Original Article

Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or Intramuscular Asparaginase Agents

Zachery Halford, PharmD, BCOP, BCPPS; Megan Park, PharmD, MBA, DPLA

Subcutaneous versus Intravenous Granulocyte Colony-Stimulating Factor to Enhance Neutrophil Engraftment in Patients Undergoing Hematopoietic Stem-Cell Transplant

Samantha L. Ellingson, PharmD, BCPS; Diwura Owolabi, PharmD, BCOP; Susan Wheelis, PharmD, BCOP; Carrie S. Oliphant, PharmD, FCCP, BCPS, BCCP; Yasser Khaled, MD

Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing

Joshua A. Roth, PhD, MHA; Theo deVos, PhD; Scott D. Ramsey, MD, PhD

FDA Oncology Update

Recent Cancer Drugs Approved by the FDA

ASH Highlights

Meeting Highlights

Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy

Meeting Highlights

Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy Prevents Cytokine Release Syndrome

Meeting Highlights

Zanubrutinib, Next-Generation BTK, Leads to Impressive Responses in Patients with CLL or SLL

Meeting Highlights